| DB ID | MyCo_1051 |
| Title | Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis |
| Year | 2015 |
| PMID | 25903568 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The work was ethically approved by the East London & the City Local Research Ethics Committee (REC reference number 05/ Q0603/6 and, as amended on 28 October 2009, reference ReDA 003933 QM). All patients in the Barts study cohort gave informed written con- sent. BAL fluid samples from the Innsbruck University Hospital were obtained during routine diagnostic investigations and analyzed anony-mously. This study was approved by the local ethics committee, Medical University Innsbruck (UN4529/308/4.1). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Aspergillus LFD |
| Biomarker Full Name | Aspergillus LFD |
| Biomarker Type | Diagnostic |
| Biomolecule | None |
| Geographical Location | UK |
| Cohort | This retrospective study comprised 32 BAL fluid samples from 32 immunocompromised adults (patients with proven IPA, n 8; patients with probable IPA, n 3; patients with possible IPA, n 6; patients with no IPA, n 15), and the study had no impact on patient management. |
| Cohort No. | 32 |
| Age Group | None |
| P Value | None |
| Sensitivity | 1 |
| Specificity | 0.8667 |
| Positive Predictive Value | 0.8 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal disease (IFD) is a major cause of infectious mor- tality in hemato-oncology patients due to their underlying dis- ease and its treatment, which lead to periods of prolonged immu- nosuppression. Invasive pulmonary aspergillosis (IPA) is the most common cause of mortality due to mold disease, and early diagnosis and treatment are vital for improving outcomes. However, early diagnosis is hampered by the limitations of current biomarker tests and a lack of consensus on the best sam- ples to be tested (i.e., blood, bronchoalveolar [BAL] fluid, or tissue biopsy specimens) in terms of both test sensitivity and practica- bility. Direct examination or culture of pulmonary tissue remains the “gold standard” for the diagnosis of IPA. |
| Technique | Assay |
| Analysis Method | Platelia Aspergillus enzyme immunoassay (PA-EIA; Bio-Rad,France) |
| ELISA kits | Platelia Aspergillus enzyme immunoassay (PA-EIA; Bio-Rad,France) |
| Assay Data | None |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA, Aspergillus lateral-flow device, Aspergillus PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
